Lex Bakker Biography and Net Worth

SVP of Merus

Lex Bakker holds a Ph.D. in Tumor Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute (Palo Alto, CA). Prior to joining Merus, Lex worked at Crucell NV, where he directed the preclinical and clinical development of a human antibody combination for rabies post-exposure prophylaxis.

How do I contact Lex Bakker?: The corporate mailing address for Mr. Bakker and other Merus executives is YALELAAN 62, UTRECHT P7, 3584 CM. Merus can also be reached via phone at (130) 253-8800 and via email at [email protected]. Learn More on Lex Bakker's contact information.
Has Lex Bakker been buying or selling shares of Merus?: Lex Bakker has not been actively trading shares of Merus within the last three months. Most recently, Lex Bakker sold 3,860 shares of the business's stock in a transaction on Thursday, July 1st. The shares were sold at an average price of $21.05, for a transaction totalling $81,253.00. Learn More on Lex Bakker's trading history.
Who are Merus' active insiders?: Merus' insider roster includes Lex Bakker (SVP), and Kruif de Kruif (SVP). Learn More on Merus' active insiders.
Are insiders buying or selling shares of Merus?: In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 23,651 shares worth more than $589,202.70. The most recent insider tranaction occured on December, 19th when VP Harry Shuman sold 115 shares worth more than $3,068.20. Insiders at Merus own 4.3% of the company. Learn More about insider trades at Merus.
Information on this page was last updated on 12/19/2023.

Lex Bakker Insider Trading History at Merus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2021	Sell	3,860	$21.05	$81,253.00

Lex Bakker Buying and Selling Activity at Merus

Merus Company Overview

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Today's Range

Now: $40.47

$39.98

$41.38

50 Day Range

MA: $45.11

$40.31

$51.82

2 Week Range

Now: $40.47

$18.21

$52.03

Volume

243,100 shs

Average Volume

568,657 shs

Market Capitalization

$2.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story